Aten Porus Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 9.89 Cr
as on 17-11-2024
- Company Age 11 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 M
as on 17-11-2024
- Revenue 37.50%
(FY 2023)
- Profit 33.21%
(FY 2023)
- Ebitda 40.54%
(FY 2023)
- Net Worth 22.19%
(FY 2023)
- Total Assets 28.67%
(FY 2023)
About Aten Porus Lifesciences
The Corporate was formerly known as Aten Biotherapeutics Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 9.89 Cr.
The company currently has active open charges totaling ₹9.00 M.
Namala Srinivasan, Aditya Kulkarni, and Arun Papaiah serve as directors at the Company.
- CIN/LLPIN
U73200KA2013PTC070323
- Company No.
070323
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Jul 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aten Porus Lifesciences?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Papaiah  | Managing Director | 25-Jul-2013 | Current |
| Aditya Kulkarni | Managing Director | 25-Jul-2013 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Namala Srinivasan | Director | 11-Feb-2014 | Current |
Financial Performance of Aten Porus Lifesciences.
Aten Porus Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 37.5% increase. The company also saw a substantial improvement in profitability, with a 33.21% increase in profit. The company's net worth Soared by an impressive increase of 22.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aten Porus Lifesciences?
In 2023, Aten Porus Lifesciences had a promoter holding of 66.67% and a public holding of 33.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hyderabad Angels Forum For Entrepreneurship DevelopmentActive 12 years 6 monthsNamala Srinivasan is a mutual person
Avammune Lifesciences Private LimitedActive 2 months 2 daysNamala Srinivasan, Aditya Kulkarni and 1 more are mutual person
- Aten Biotech Private LimitedActive 11 years 7 months
Aditya Kulkarni and Arun Papaiah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 10 Aug 2022 | ₹9.00 M | Open |
How Many Employees Work at Aten Porus Lifesciences?
Aten Porus Lifesciences has a workforce of 20 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aten Porus Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aten Porus Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
